Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients

Yen-Chun Liu^{1

2}, Wen-Juei Jeng^{1

2}

Affiliations

¹ College of Medicine, Chang Gung University, Taipei, Taiwan.
² Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan.

Editorial

Yen-Chun Liu et al. Aliment Pharmacol Ther. 2023 Mar.

. 2023 Mar;57(5):577-578.

doi: 10.1111/apt.17340.

Yen-Chun Liu^{1

2}, Wen-Juei Jeng^{1

2}

¹ College of Medicine, Chang Gung University, Taipei, Taiwan.
² Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan.

No abstract available

Comment on

Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone.
Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, Liu Y, Xue R, Zhan J, Jiang S, Geng Y, Wan Y, Li M, Mao M, Gao D, Yin S, Tong X, Xia J, Ding W, Chen Y, Li J, Zhu C, Huang R, Wu C. Wang J, et al. Aliment Pharmacol Ther. 2023 Mar;57(5):464-474. doi: 10.1111/apt.17272. Epub 2022 Nov 2. Aliment Pharmacol Ther. 2023. PMID: 36324235

1. Bonacci M, Lens S, Marino Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey zone. Aliment Pharmacol Ther. 2018;47(10):1397-408.
1. Teng W, Chang TT, Yang HI, Peng CY, Su CW, Su TH, et al. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatol Int. 2021;15(6):1421-30.
1. Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol. 2015;13(1):193-201 e191.
1. Huang DQ, Lee DH, Le MH, et al. Liver complications in untreated treatment-ineligible versus treated treatment-eligible patients with hepatitis B. Dig Dis. 2023;41:115-23. https://doi.org/10.1159/000526933
1. Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther. 2023;57(5):464-74